This Cancer Cachexia - Pipeline Insight, 2021 provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Cancer Cachexia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Cancer cachexia is a wasting syndrome characterized by weight loss, anorexia, asthenia and anemia. The pathogenicity of this syndrome is multifactorial, due to a complex interaction of tumor and host factors. The signs and symptoms of cachexia are considered as the prognostic parameters in cancer patients. Cancer cachexia most often affects patients with cancers of the upper gastrointestinal tract, including the esophagus, stomach, and pancreas. Not all cancer patients are affected equally by cachexia. There are three stages of cachexia: Precachexia - weight loss of less than 5% of body weight, Cachexia - weight loss greater than 5% of body weight, Refractory Cachexia - refers to patients with cachexia whose cancer treatments are no longer working and have a life expectancy of less than 3 months. Drastic weight loss can be a risk factor for poor survival of a cancer diagnosis. Cachectic patients have worse outcomes with surgery, chemotherapy, and radiation therapy. Cachexia can be treated by better managing symptoms that affect appetite, including nausea, pain and constipation. Treatments can attempt to stimulate the appetite with medications like synthetic hormones and corticosteroids.
Cancer Cachexia - Pipeline Insight, 2021 report by the publisher outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Cancer Cachexia pipeline landscape is provided which includes the disease overview and Cancer Cachexia treatment guidelines. The assessment part of the report embraces, in depth Cancer Cachexia commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Cancer Cachexia collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
The companies and academics are working to assess challenges and seek opportunities that could influence Cancer Cachexia R&D. The therapies under development are focused on novel approaches to treat/improve Cancer Cachexia.
This segment of the Cancer Cachexia report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Macimorelin: AEterna Zentaris
Macimorelin (AEZS 130) is an orally active, small-molecule, being developed by AEterna Zentaris for the diagnosis of adult and pediatric growth hormone deficiency (AGHD; PGHD) [somatotropin deficiency in development table] and for the treatment of cachexia associated with chronic diseases, such as AIDS and cancer. Macimorelin was approved by the FDA in December 2017 under the market name Macrilen for oral solution. Macimorelin stimulates GH release by activating growth hormone secretagogue receptors present in the pituitary and hypothalamus. The drug is currently being investigated in Phase II clinical to treat patients with Cancer Cachexia.
PF- 06946860: Pfizer
PF- 06946860 is a Growth Factor Blocker being investigated in Phase I stage of development. A 6 week double blind study to compare the effects of the investigational new drug (PF-06946860) and a placebo on appetite has been initiated to find out how participants with advanced cancer and anorexia feel after receiving repeated doses injected under the skin.
There are approx. 15+ key companies which are developing the therapies for Cancer Cachexia. The companies which have their Cancer Cachexia drug candidates in the most advanced stage, i.e. Phase II include, AEterna Zentaris.
The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Cancer Cachexia therapeutic drugs key players involved in developing key drugs.
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Cancer Cachexia drugs.
Geography Covered
- Global coverage
Cancer Cachexia Understanding
Cancer Cachexia: Overview
Cancer cachexia is a wasting syndrome characterized by weight loss, anorexia, asthenia and anemia. The pathogenicity of this syndrome is multifactorial, due to a complex interaction of tumor and host factors. The signs and symptoms of cachexia are considered as the prognostic parameters in cancer patients. Cancer cachexia most often affects patients with cancers of the upper gastrointestinal tract, including the esophagus, stomach, and pancreas. Not all cancer patients are affected equally by cachexia. There are three stages of cachexia: Precachexia - weight loss of less than 5% of body weight, Cachexia - weight loss greater than 5% of body weight, Refractory Cachexia - refers to patients with cachexia whose cancer treatments are no longer working and have a life expectancy of less than 3 months. Drastic weight loss can be a risk factor for poor survival of a cancer diagnosis. Cachectic patients have worse outcomes with surgery, chemotherapy, and radiation therapy. Cachexia can be treated by better managing symptoms that affect appetite, including nausea, pain and constipation. Treatments can attempt to stimulate the appetite with medications like synthetic hormones and corticosteroids.
Cancer Cachexia - Pipeline Insight, 2021 report by the publisher outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Cancer Cachexia pipeline landscape is provided which includes the disease overview and Cancer Cachexia treatment guidelines. The assessment part of the report embraces, in depth Cancer Cachexia commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Cancer Cachexia collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
The companies and academics are working to assess challenges and seek opportunities that could influence Cancer Cachexia R&D. The therapies under development are focused on novel approaches to treat/improve Cancer Cachexia.
Cancer Cachexia Emerging Drugs Chapters
This segment of the Cancer Cachexia report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Cancer Cachexia Emerging Drugs
Macimorelin: AEterna Zentaris
Macimorelin (AEZS 130) is an orally active, small-molecule, being developed by AEterna Zentaris for the diagnosis of adult and pediatric growth hormone deficiency (AGHD; PGHD) [somatotropin deficiency in development table] and for the treatment of cachexia associated with chronic diseases, such as AIDS and cancer. Macimorelin was approved by the FDA in December 2017 under the market name Macrilen for oral solution. Macimorelin stimulates GH release by activating growth hormone secretagogue receptors present in the pituitary and hypothalamus. The drug is currently being investigated in Phase II clinical to treat patients with Cancer Cachexia.
PF- 06946860: Pfizer
PF- 06946860 is a Growth Factor Blocker being investigated in Phase I stage of development. A 6 week double blind study to compare the effects of the investigational new drug (PF-06946860) and a placebo on appetite has been initiated to find out how participants with advanced cancer and anorexia feel after receiving repeated doses injected under the skin.
Cancer Cachexia: Therapeutic Assessment
This segment of the report provides insights about the different Cancer Cachexia drugs segregated based on following parameters that define the scope of the report, such as:
Major Players in Cancer Cachexia
There are approx. 15+ key companies which are developing the therapies for Cancer Cachexia. The companies which have their Cancer Cachexia drug candidates in the most advanced stage, i.e. Phase II include, AEterna Zentaris.
Phases
This report covers around 15+ products under different phases of clinical development like
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Cancer Cachexia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Oral
- Parenteral
- Intravenous
- Subcutaneous
- Topical
- Molecule Type
Products have been categorized under various Molecule types such as
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Cancer Cachexia: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Cancer Cachexia therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Cancer Cachexia drugs.
Cancer Cachexia Report Insights
- Cancer Cachexia Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
Cancer Cachexia Report Assessment
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Key Questions Answered
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Cancer Cachexia drugs?
- How many Cancer Cachexia drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Cancer Cachexia?
- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Cancer Cachexia therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Cancer Cachexia and their status?
- What are the key designations that have been granted to the emerging drugs?
Table of Contents
IntroductionExecutive Summary
Cancer Cachexia: Overview
- Causes
- Mechanism of Action
- Signs and Symptoms
- Diagnosis
- Disease Management
Pipeline Therapeutics
- Comparative Analysis
Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
Late Stage Products (Phase III)
- Comparative Analysis
Macimorelin: AEterna Zentaris
- Product Description
- Research and Development
- Product Development Activities
Mid Stage Products (Phase II)
- Comparative Analysis
Drug Name: Company Name
- Product Description
- Research and Development
- Product Development Activities
Early stage products (Phase I)
- Comparative Analysis
PF- 06946860: Pfizer
- Product Description
- Research and Development
- Product Development Activities
Inactive Products
- Comparative Analysis
Cancer Cachexia Key Companies
Cancer Cachexia Key Products
Cancer Cachexia- Unmet Needs
Cancer Cachexia- Market Drivers and Barriers
Cancer Cachexia- Future Perspectives and Conclusion
Cancer Cachexia Analyst Views
Cancer Cachexia Key Companies
AppendixList of Tables
Table 1 Total Products for Cancer Cachexia
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive ProductsList of Figures
Figure 1 Total Products for Cancer Cachexia
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Companies Mentioned
A selection of companies mentioned in this report includes:
- AEterna Zentaris
- Pfizer
- Incyte Corporation
- Smartfish AS
- NGM Biopharmaceuticals
- Caelus Health
- Helsinn Therapeutics/Ono Pharmaceutical
- Aphios Corporation
- Actimed Therapeutics
- Ildong Pharmaceutical
- Tetra Biopharma
- Aveo Oncology
